Lymph node biopsy in resource-limited breast cancer systems: a scoping review of non-nuclear mapping, implementation and outcomes

This study aimed to map non-nuclear sentinel lymph node biopsy techniques for breast cancer in resource-limited systems and synthesise implementation requirements and outcomes. Scoping review following Joanna Briggs Institute guidance and PRISMA-ScR. Setting: Services meeting a service-level definition of resource limitation; low- or middle-income country location alone was insufficient. Information sources: PubMed, Europe PMC and backward citation searching. Subjects: Clinical studies, implementation reports, surveys, reviews and guidelines on axillary staging. Outcome measures: Identification, false-negative performance, morbidity, axillary dissection avoided, cost, barriers and training. The merged database exports contained 2,301 records; 1,252 unique records were screened and 36 evidence sources included. Methylene blue (MB) programmes reported 85.7%–100% identification, with a 13% false-negative rate in one meta-analysis. Fluorescein plus MB achieved 82%–100% identification with false-negative rates of 6.3%–8.7%. Indocyanine green series achieved 95.7%–100% identification but required near-infrared equipment. Gentian violet achieved 97.5% identification in a small cohort. Ethiopian programmes achieved 100% identification; one avoided axillary dissection in 80%. North African data showed less lymphoedema after sentinel biopsy than dissection (3.8% versus 23.0%). Constraints were nuclear medicine, pathology, supply, training and follow-up. Non-nuclear sentinel node biopsy appears feasible in resource-limited services when introduced as a governed pathway rather than dye substitution. MB was the lowest-cost/lowest-infrastructure option identified; fluorescein plus MB adds redundancy, while indocyanine green suits services able to support reusable imaging. Evidence is insufficient to establish oncological equivalence. Prospective implementation studies with audited recurrence, morbidity and cost are required.

Authors

Publication Details

Journal
International Surgery Journal
Published
2026-10-27
DOI
https://doi.org/10.18203/2349-2902.isj20263877
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lymph node biopsy in resource-limited breast cancer systems: a scoping review of non-nuclear mapping, implementation and outcomes

Hridhay Somera
2 links
International Surgery Journal
Breast Cancer Treatment Studies
article

Lymph node biopsy in resource-limited breast cancer systems: a scoping review of non-nuclear mapping, implementation and outcomes

Hridhay Somera
article en

Abstract

This study aimed to map non-nuclear sentinel lymph node biopsy techniques for breast cancer in resource-limited systems and synthesise implementation requirements and outcomes. Scoping review following Joanna Briggs Institute guidance and PRISMA-ScR. Setting: Services meeting a service-level definition of resource limitation; low- or middle-income country location alone was insufficient. Information sources: PubMed, Europe PMC and backward citation searching. Subjects: Clinical studies, implementation reports, surveys, reviews and guidelines on axillary staging. Outcome measures: Identification, false-negative performance, morbidity, axillary dissection avoided, cost, barriers and training. The merged database exports contained 2,301 records; 1,252 unique records were screened and 36 evidence sources included. Methylene blue (MB) programmes reported 85.7%–100% identification, with a 13% false-negative rate in one meta-analysis. Fluorescein plus MB achieved 82%–100% identification with false-negative rates of 6.3%–8.7%. Indocyanine green series achieved 95.7%–100% identification but required near-infrared equipment. Gentian violet achieved 97.5% identification in a small cohort. Ethiopian programmes achieved 100% identification; one avoided axillary dissection in 80%. North African data showed less lymphoedema after sentinel biopsy than dissection (3.8% versus 23.0%). Constraints were nuclear medicine, pathology, supply, training and follow-up. Non-nuclear sentinel node biopsy appears feasible in resource-limited services when introduced as a governed pathway rather than dye substitution. MB was the lowest-cost/lowest-infrastructure option identified; fluorescein plus MB adds redundancy, while indocyanine green suits services able to support reusable imaging. Evidence is insufficient to establish oncological equivalence. Prospective implementation studies with audited recurrence, morbidity and cost are required.

International Surgery JournalVol. 13(11)
Good health and well-being
Openalex Percentile: Top 17%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Lymph node biopsy in resource-limited breast cancer systems: a scoping review of non-nuclear mapping, implementation and outcomes — Hridhay Somera · International Surgery Journal (2026) | TGRS Research Map | TGRS